Dr. Andrew John Nichols Ph.D. serves as Chief Scientific Officer of the Company. Dr. Nichols was Associate Vice President, Cardiometabolic Diseases at Merck Research Labs, a pharmaceutical research company, leading drug discovery and early clinical development programs. Dr. Nichols was also Associate Vice President/Executive Director, In Vivo Pharmacology at Merck Research Labs from August 2010 to October 2013, and Executive Director, In Vivo Sciences at Merck Research Labs from August 2009 to August 2010. Prior to Merck, Dr. Nichols was Vice President of Preclinical Research at Zafgen, Vice President of Research at Alinea, Vice President of Drug Discovery Project Leadership at Millennium and Director of the Alliance Management Group at SmithKline Beecham. He holds an M. Phil. and Ph.D. in Cardiovascular Pharmacology from the University of Cambridge, England and a B.Sc. in Pharmacology from the University of Leeds, England.
As the Chief Scientific Officer of Astria Therapeutics Inc, the total compensation of Andrew Nichols at Astria Therapeutics Inc is $631,945. There are 2 executives at Astria Therapeutics Inc getting paid more, with Jill Milne having the highest compensation of $1,032,800.
Andrew Nichols is 59, he's been the Chief Scientific Officer of Astria Therapeutics Inc since 2016. There are 5 older and 4 younger executives at Astria Therapeutics Inc. The oldest executive at Astria Therapeutics Inc is Michael Kishbauch, 71, who is the Independent Director.
Andrew's mailing address filed with the SEC is 1 Kendall Square B14202, Cambridge, MA 02139, USA.
Over the last 9 years, insiders at Astria Therapeutics Inc have traded over $0 worth of Astria Therapeutics Inc stock and bought 3,064,797 units worth $36,777,564 . The most active insiders traders include Jean George, Nicholas Galakatos a Lifesciences Ii, L.P.Clarus.... On average, Astria Therapeutics Inc executives and independent directors trade stock every 0 days with the average trade being worth of $2,617,339. The most recent stock trade was executed by Lifesciences Ii, L.P.Clarus... on 30 June 2015, trading 376,695 units of CATB stock currently worth $4,520,340.
Astria Therapeutics Inc executives and other stock owners filed with the SEC include: